Prescribing information

 

       

This page hosts downloadable items to help you educate your patient on the ENERZAIR® BREEZHALER® (indacaterol acetate/glycopyrronium bromide/mometasone furoate inhalation powder) device. 

Your Choice with KISQALI logo

THE USE OF THE ENERZAIR BREEZHALER DEVICE

 

View

 

Screenshot of Patient Information Booklet

PATIENT INFORMATION BOOKLET ON ENERZAIR AND SENSOR

 

Preview

 

PODCAST

Our podcast series foucuses on the unmet needs in asthma – Why do patients remain uncontrolled?1-6

Learn more

 

Indication: ENERZAIR BREEZHALER is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.7

References

  1. Buhl R, et al. Respir Med 2020;162:105859.
  2. WHO. Available from: https://www.who.int/news-room/fact-sheets/detail/asthma [Accessed November 2020].
  3. Kerstjens HA, et al. N Engl J Med 2012;367:1198–207.
  4. Kerstjens HA, et al. Respir Med 2016;117:198–206.
  5. Azzi E et al. NPJ Prim Care Respir Med 2017;27:29.
  6. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2014. Available from: https://ginasthma.org/wp-content/uploads/2019/01/2014-GINA.pdf [Accessed November 2020].
  7. ENERZAIR BREEZEHALER Summary of Product Characteristics.
ENE20-C008 November 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]